Advent International, a private equity firm, agreed to invest in Iodine, a healthcare AI company, at a $1bn valuation. Bain Capital Ventures and Silversmith Capital Partners will remain shareholders. "Utilizing advancing technology to scale hospital resources, ease administrative burden, and maximize reimbursement is more important than ever,. We’ve always been committed to building the most powerful, predictive tools available. This investment provides access to capital for expansion and growth strategies so that we can innovate faster and find more ways to empower healthcare leaders to meet with confidence the delicate balance of quality, efficiency, and system financial resilience," William Chan, Iodine CEO and Co-Founder.